Current treatment of chronic hepatitis B: Benefits and limitations

Seminars in Liver Disease

Volumn 25, Issue SUPPL. 1, 2005, Pages 20-28

  Perrillo, Robert P ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Clinical trials; Hepatitis B; Interferon; Nucleoside analogues

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; EMTRICITABINE; ENTECAVIR; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

CLINICAL TRIAL; DNA DETERMINATION; DRUG APPROVAL; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; EUROPE; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UNITED STATES; VIRUS INHIBITION; VIRUS RESISTANCE;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B, CHRONIC; HUMANS; PRACTICE GUIDELINES; REFERENCE VALUES; VIRAL LOAD;

EID: 24344444416     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-915647     Document Type: Review

References (59)

1. Lok ASF, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004;39:857-861
2. Y-F Liaw, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472-489
3. EASL Jury. EASL International Consensus Conference on Hepatitis B: 13-14 September 2002, Geneva, Switzerland: consensus statement (long version). J Hepatol 2003;39:S3-S25
4. Chu C-J, Hussain M, Lok ASF. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002;36:1408-1415
5. Manensis EK, Papatheodoridis GV, Sevastianos V, et al. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 2003;98:2261-2267
6. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-194
7. Piton A, Poynard T, Imbert-Bismut F, et al, for the MULTIVIRC Group. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology 1998;27: 1213-1219
8. Yang LM, Xu KC, Zhao YL, et al. Clinical significance of liver biopsy in chronic hepatitis B patients with persistently normal transaminase. Chin J Dig Dis 2002;3:150-153
9. Keeffe EB, Dieterich DT, Han S-HB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004;2:87-106
10. Yao J, Beld M, Oon L, et al. Multicenter evaluation of the VERSANT hepatitis B virus DNA 3.0 assay. J Clin Microbiol 2004;42:800-806
11. Lewin SR, Ribeiro RM, Walters T, et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001;34:1012-1020
12. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-117
13. Lok ASF, Lai C-L, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722
14. Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531
15. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005;25(suppl 1):9-19
16. Richman D. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000;32:866-867
17. Sung JJY, Lau JY, Zeuzem S, et al. A randomized double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): week 52 analysis. J Hepatol 2003;38(suppl 2):25 (abst)
18. Perrillo RP. Interferon in the management of chronic hepatitis B. Dig Dis Sci 1993;38:577-593
19. Nair S, Perrillo R. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 2001;34:1021-1026
20. Cooksley G, Manns M, Lau GKK, et al. Effect of genotype and other baseline factors on response to peginterferon alfa-2a (40 KD) (Pegasys®) in HBeAg-positive chronic hepatitis B: results from a large, randomized study. J Hepatol 2005;42:30 (abst)
21. Cooksley WG. Treatment with interferons in patients with hepatitis B. Semin Liver Dis 2004;24(suppl 1):45-54
22. Janssen HLA, van Zonneveld M, Zeuzem S, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005;365:123-129
23. Lau G, Piratvisuth T, Luo KX, et al. PEGinterferon alfa-2a (40KD) (Pegasys®) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: Results from a large multinational study. Hepatology 2004;40:171A
24. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-1217
25. Piratvisuth T, Luo K-X, Marcellin P, et al. Effect of ALT flares on efficacy and safety of PEGinterferon alfa-2a (40KD) (Pegasys®), PEGinterferon alfa-2a plus lamivudine and lamivudine in HBeAg-positive chronic hepatitis B (CHB). J Hepatol 2005;42:189 (abst)
26. Westland C, Delaney WIV, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003;125:107-116
27. Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998-1002
28. Chu CJ, Keeffe EB, Han SH, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003;125:444-451
29. Chang T-T, Hadziyannis S, Cianciara J, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology 2002;36:300A
30. Lai C-L, Leung NWY, Teo E-K, et al. Results of a one-year international phase IIB comparative trial of telbivudine, lamivudine, and the combination in patients with chronic hepatitis B. Hepatology 2003;38:262A
31. Wright TL. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin Liver Dis 2004;24(suppl 1): 31-36
32. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263
33. Liaw YF, Leung NWY, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-180
34. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis 2003;23:125-136
35. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816
36. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800-807
37. Marcellin P, Chang T, Lim S, et al. Increasing serologic, virologic and biochemical response over time to adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients. J Hepatol 2005;42:31 (abst)
38. Hadziyannis S, Tassopoulos N, Chang TT, et al. Three year study of adefovir dipivoxil demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES). J Hepatol 2004;40:17 (abst)
39. Hadziyannis S, Tassopoulos N, Heatheate EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-2681
40. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292-297
41. Perrillo R, Hann H-W, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126:81-90
42. Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-100
43. Schiff ER, Lai C-L, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419-1427
44. Lai C-L, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123: 1831-1838
45. Chang TT, Gish R, de Man R, et al. Entecavir is superior to lamivudine for the treatment of HBeAg (+) chronic hepatitis B: results of a phase III study ETV-022 in nucleoside-naïve patients. Hepatology 2004;40(suppl 1):193A (abst)
46. Shouval D, Lai C-L, Cheinquer H, et al. Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naïve HBeAg (-) chronic hepatitis B: results of a phase III trial ETV-027. Hepatology 2004;40: 728A (abst)
47. Tenney DJ, Langley DR, Oliver AJ, et al. Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase. Hepatology 2004;40:245A
48. Colonno R, Rose RE, Levine SM, et al. Entecavir (ECV) resistance is not observed in nucleoside-naïve subjects and is observed infrequently by week 48 in lamivudine-refractory subjects with chronic HBV infection. J Hepatol 2005;42:173 (abst)
49. Shiffman M, Ng TM, Krastev Z, et al. A double-blind, placebo-controlled trial of emtricitabine (FTC, Emtriva) administered once daily for treatment of chronic hepatitis B virus (HBV) infection. Hepatology 2004;40:172A (abst 22)
50. Raffi F, Snow A, Borroto-Esoda K, et al. Anti-HBV activity of emtricitabine (FTC) in patients co-infected with HIV and hepatitis B virus (abst 215). Programs and abstracts of the 2nd IAS Conference on Pathogenesis and Treatment; July 13-16, 2003; Paris, France
51. Gish R, Leung N, Wang C, et al. Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients (CHB) given once daily emtricitabine for 2 years. Hepatology 2002;36:372A
52. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-1425
53. Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002;186:1844-1847
54. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003;17:F7-10
55. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004;2:266-272
56. Perrillo RP. Overview of treatment of hepatitis B: Key approaches and clinical challenges. Semin Liver Dis 2004; 24(suppl 1):23-29
57. Sung JJY, Lai JY, Zeuzem S, et al. A randomized double-blind phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment naive patients with chronic hepatitis B: week52 analysis. J Hepatol 2003;38(suppl 2):25 (abst)
58. Lai CL, Leung NW, Teo E, et al. Phase IIb extended-treatment trial of telbivudine (LdT) vs lamivudine vs combination treatment in hepatitis B patients: two-year results. Gastroenterology 2005;128(suppl 2):320A
59. Chan HL-Y, Leung NW-Y, Hui Ay, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-α2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:240-250